• Nykode Therapeutics received Canadian regulatory approval for its Phase 2 Abili-T trial of cancer vaccine abi-suva with pembrolizumab.
• The trial targets HPV16-positive, PD-L1-positive recurrent or metastatic head and neck cancer; first interim data are expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nykode Therapeutics AS published the original content used to generate this news brief via NewsWeb, the disclosure sustem operated by Euronext Oslo (Ref. ID: 202610230200OSLOBORSNEWS__EN_2B097A87640275D30128A5D77774918), on October 23, 2026, and is solely responsible for the information contained therein.